Amgen's Myeloma Treatment Study Fails to Meet Primary Endpoint
September 27 2016 - 8:32AM
Dow Jones News
By Joshua Jamerson
Amgen on Tuesday said a study testing the use of its multiple
myeloma treatment Kyprolis in combination with other agents missed
its primary endpoint after failing to show superiority in
progression-free survival.
Shares of Amgen fell 1.5% to $171 in premarket trading.
The Phase-3 trial tested an investigational regimen of Kyprolis,
melphalan and prednisone versus a combination of Millennium
Pharmaceuticals Inc.'s cancer drug Velcade with melphalan and
prednisone. Premature data for overall survival, a secondary
endpoint, wasn't statistically significant, the company said.
Sean Harper, Amgen's executive vice president of research and
development, said the results "are disappointing" but the company
will continue to explore Kyprolis in combination with other
agents.
Kyprolis is approved in the U.S., in combination with other
agents, for the treatment of patients with relapsed or refractory
multiple myeloma who have received one to three lines of therapy.
It is also approved as a single agent for treating patients with
relapsed or refractory multiple myeloma who have received one or
more lines of therapy.
A Phase-3 study evaluating Kyprolis in combination with
lenalidomide plus dexamethasone versus Velcade and Velcade in
combination with lenalidomide plus dexamethasone is currently
underway.
Write to Joshua Jamerson at joshua.jamerson@wsj.com
(END) Dow Jones Newswires
September 27, 2016 08:17 ET (12:17 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
